Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

• Status: Completed
• Trial end date: 2020-10-07

Summary

The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.

• Phase: Phase 3

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Epoetin Alfa; Prolyl-Hydroxylase Inhibitors